Mitral Valve

The heart's mitral valve is the site of the most surgical valve repairs and valve replacements. After the resounding success of transcatheter aortic valve replacement (TAVR), which now makes up more than 50% of aortic valve replacements, there is wide expectation transcatheter mitral replacements will follow in the next few year. Currently, the most common transcatheter mitral procedure is transcatheter edge-to-edge (TEER) , using the MitraClip or Pascal clip devices. These devices are also being used for transcatheter tricuspid valve repair (TTVR). Other transcatheter mitral repair systems are in trials for minimally invasive annuloplasty and chordae tendineae repair.

Low-volume operators linked to worse outcomes after TAVR, M-TEER
Researchers tracked data from more than 400,00 patients, sharing their findings in JAMA Cardiology.
FDA approves TMVR system from Edwards Lifesciences for high-risk heart patients
The Sapien M3 transcatheter mitral valve replacement system is implanted using a transseptal approach. The device previously received CE mark approval in 2025.
M-TEER still beneficial for high-risk patients with smaller mitral valve areas
Mitral valve surgery can be especially challenging when patients present with a small mitral valve area. When it comes to M-TEER, however, treatment still appears to be both safe and effective.
New technique could help when cardiologists repair 2 leaky heart valves at once
Performing M-TEER and T-TEER on the same patient using a single guide catheter appears to be both safe and effective. Researchers shared their experience with this approach in Circulation: Cardiovascular Interventions.
Mitral annular calcification linked to higher heart failure risks
In fact, researchers wrote, MAC appears to influence a patient's odds of developing HFpEF even more than their BMI.

TEER benefits all HF patients with SMR, but men see more long-term benefits

The study's authors examined data from men and women who underwent TEER with the MitraClip device in addition to guideline-directed medical therapy.

Valve-in-valve TMVR an effective option for patients with mitral prosthesis dysfunction

Adjusted mortality and perioperative complications were both lower among patients undergoing ViV TMVR.

Survival rates similar when treating secondary MR with TEER or surgery

Surgical mitral valve repair, however, was also associated with multiple benefits.

TMVR outcomes suffer when patients have heart failure and diabetes—but benefits remain

Overall, the authors emphasized, TMVR helped heart failure patients with and without diabetes.

Next-day discharge after TMVR is on the rise

By 2018, nearly half of all TMVR patients were going home the very next day. Outcomes for these patients have been consistently positive.

TEER shows potential to boost outcomes for cardiogenic shock patients

Cardiogenic shock has been linked to a heightened risk of morbidity and mortality. TEER, it seems, may be able to help provide patients with some relief.

How diabetes impacts TEER outcomes

The new analysis, published in JACC: Heart Failure, focused on patient data from the renowned COAPT trial.

Risk score predicts outcomes for heart failure patients undergoing TEER

The new analysis included data from nearly 700 patients who underwent TEER, formerly known as TMVR, over an eight-year period.

Mitral Valve

Low-volume operators linked to worse outcomes after TAVR, M-TEER

FDA approves TMVR system from Edwards Lifesciences for high-risk heart patients

M-TEER still beneficial for high-risk patients with smaller mitral valve areas

New technique could help when cardiologists repair 2 leaky heart valves at once

Mitral annular calcification linked to higher heart failure risks